Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.68 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | LAP3 | P28838 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789070 | 1.00 | PPARG (0.68) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL3787409 | 0.90 | PPARG (0.56) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL8842542 | 0.90 | PPARG (0.65) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL3787413 | 0.90 | PPARG (0.56) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL9109075 | 0.85 | HPGDS (0.56) | MME | |
| SCHEMBL792956 | 0.84 | BCL2 (0.64) | PPARGACEPPARA | |
| SCHEMBL27330427 | 0.84 | PPARG (0.62) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL7315978 | 0.84 | PPARG (0.56) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL7315990 | 0.84 | PPARG (0.56) | PPARGGPR34MMP9MMP8LTA4H | |
| SCHEMBL20268332 | 0.84 | MMP9 (0.78) | PPARGGPR34MMP9MMP8LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | PPARG 736/4885GPR34 4329/4885MMP9 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.